Literature DB >> 7728772

Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.

A Cesano1, S Visonneau, L Cioé, S C Clark, D Santoli.   

Abstract

The TALL-104 cell line, originally derived from a patient with T cell leukemia, can be maintained indefinitely in culture in the presence of interleukin-2 (IL-2) and is endowed with a highly potent major-histocompatibility-complex (MHC)-non-restricted tumoricidal activity both in vitro and in animal models. The present study analyzes in detail the short- and long-term effects of irradiation and cyclosporin A (CsA) treatment on the growth and tumoricidal function of this T cell clone as compared to polyclonal lymphokine-activated killer (LAK) cell preparations from healthy donors. DNA and RNA syntheses by both TALL-104 and LAK cells were irreversibly arrested a few hours after irradiation with 40 Gy. However, 4-h 51Cr-release assays, performed on different days (day 1 to day 7) after irradiation, showed that the cytotoxic efficiency of TALL-104 cells against hematopoietic and solid tumor targets was only modestly reduced, whereas that of LAK cells was severely inhibited. Moreover, the cytotoxic responses to recombinant human IL-2 and IL-12, measured 18 h after irradiation and cytokine addition, were normal in the case of TALL-104 cells but were abolished in the case of LAK cells. Co-culture of IL-2- or IL-12-preactivated TALL-104 cells with a tumor target for 5 days in the absence of cytokines resulted in a lower efficiency of lysis, as compared to the non-irradiated effectors, especially if the initial stimulus was IL-12. These findings suggest the requirement of multiple cytokine stimulation for optimal expression of tumoricidal activity by lethally irradiated TALL-104 cells. CsA, while abrogating TALL-104 cell proliferation at the low dose of 0.5 microgram/ml, inhibited their cytotoxic function marginally only at high doses (100 micrograms/ml). By contrast, CsA reduced dose-dependently the cytotoxicity of LAK cells starting at very low doses (0.5 microgram/ml). CsA did not impair the ability of TALL-104 and LAK cells to produce interferon (IFN) gamma, tumor necrosis factor (TNF) alpha, and granulocyte/macrophage-colony-stimulatory factor (GM-CSF) in response to IL-2, IL-12, or tumor targets. Irradiation reduced drastically IFN gamma production by LAK, but not TALL-104 cells; release of TNF alpha and GM-CSF by either type of effector was inhibited by 10%-50%, depending on the stimulus. The high resistance and immunosuppressive drugs renders tis immortal T cell clone a potentially safe and effective reagent for new adoptive-transfer approaches to cancer in MHC-incompatible recipients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7728772     DOI: 10.1007/bf01517345

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  34 in total

1.  Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice.

Authors:  A Cesano; R O'Connor; B Lange; J Finan; G Rovera; D Santoli
Journal:  Blood       Date:  1991-06-01       Impact factor: 22.113

2.  The combined effect of lymphokine activated killer cell and radiation therapy on rat brain tumor in vitro.

Authors:  K Nakagawa; N Omori; K Hashimoto; T Yamamoto; T Tsunoda; T Nose
Journal:  Biotherapy       Date:  1992

3.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

4.  Cloning and chromosomal assignment of a human cDNA encoding a T cell- and natural killer cell-specific trypsin-like serine protease.

Authors:  H K Gershenfeld; R J Hershberger; T B Shows; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

5.  Molecular cloning of an inducible serine esterase gene from human cytotoxic lymphocytes.

Authors:  J A Trapani; J L Klein; P C White; B Dupont
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

6.  The effect of in vitro irradiation on human NK cell activity. A preliminary report.

Authors:  J N Halpern; E Cohen; T Mekori; A N Beny; A Kuten; E A Rosenblatt; E Robinson
Journal:  J Med       Date:  1991

7.  Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.

Authors:  A Cesano; S Visonneau; L Cioé; S C Clark; G Rovera; D Santoli
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

8.  Lymphoid irradiation results in long-term increases in natural killer cells in patients treated for Hodgkin's disease.

Authors:  R M Macklis; P M Mauch; S J Burakoff; B R Smith
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

9.  Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.

Authors:  Y Kaufmann; M Levanon; J Davidsohn; B Ramot
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

10.  Radiosensitivity of NK lytic activities and NK-mediated hematopoietic colony inhibition: effect of activation with IL-2 and blocking of the T-200 molecule.

Authors:  C A Keever; E Benazzi; N A Kernan; K Welte; R J O'Reilly; C Bordignon
Journal:  Cell Immunol       Date:  1988-04-15       Impact factor: 4.868

View more
  2 in total

Review 1.  Immunologic approaches to therapy for brain tumors.

Authors:  D B Paul; C A Kruse
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

2.  Multimodal investigations of trans-endothelial cell trafficking under condition of disrupted blood-brain barrier integrity.

Authors:  Nicola Marchi; Qingshan Teng; Minh T Nguyen; Linda Franic; Nirav K Desai; Thomas Masaryk; Peter Rasmussen; Silvia Trasciatti; Damir Janigro
Journal:  BMC Neurosci       Date:  2010-03-09       Impact factor: 3.288

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.